Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Ocugen

< Previous 1 2 3 4 Next >
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen CEO to Present at NobleCon19 – Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST—Modifier Gene Therapy—for Stargardt Disease
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen Provides Business Update with Third Quarter 2023 Financial Results
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen CSO to Participate in 4th Annual Dry AMD Therapeutic Development Summit
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen to Host Conference Call on Thursday, November 9 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2023 Financial Results
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen Mucosal Vaccine Candidate OCU500 Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen to Present at the 2023 Cell & Gene Meeting on the Mesa
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen CSO to Participate in 4th Annual Gene Therapy for Ophthalmic Disorders Conference
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines Conference
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen, Inc. Announces Connie Collingsworth Joins Business Advisory Board
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen to Participate in Panel at Cantor Fitzgerald Global Healthcare Conference 2023
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen to Host Virtual Investor & Analyst Event on September 13, 2023
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen Provides Business Update with Second Quarter 2023 Financial Results
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen to Host Conference Call on Tuesday, August 22 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2023 Financial Results
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen CEO & CSO to Present at 41st Annual AAPI Convention and Scientific Assembly
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen, Inc. Announces Adjournment of Annual Meeting of Shareholders
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen, Inc. Announces Business Advisory Board
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen, Inc. Announces Pricing of $16.5 Million Public Offering of Common Stock
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen, Inc. Announces Proposed Public Offering of Common Stock
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen to Present at BIO International Convention 2023
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen Provides Business Update with First Quarter 2023 Financial Results
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen to Host Conference Call on Friday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2023 Financial Results
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen Announces OCU410ST Receives Orphan Drug Designation for Treatment of ABCA4-Associated Retinopathies
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen, Inc. to Participate in Fireside Chat at the H.C. Wainwright BioConnect Investor Conference
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen to Present at Association for Research in Vision and Ophthalmology 2023 Annual Meeting
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen Announces Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen to Host Virtual Investor & Analyst Event on April 14, 2023
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen Chief Scientific Officer to Present at 2023 World Vaccine Congress
From Ocugen
Via GlobeNewswire
Tickers OCGN
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.